Buy EMBC by Oct 13, 2026.

**But there is also some positive news.** At the end of the article, they themselves list several factors that could support Embecta: partnerships with more than **30 pharmaceutical companies**; joint projects related to **GLP-1 and pen needles**; emerging markets; cost savings from restructuring; ERP integration; potential future revenue growth. **In other words, even the authors of the article acknowledge the presence of long-term growth drivers.** **What personally caught my attention** There is a small contradiction. They: significantly increase their future …